Curated News
By: NewsRamp Editorial Staff
August 14, 2026
SS Innovations Hits Record Q2 Revenue of $13.9M, Up 39.4%
TLDR
- SS Innovations' record Q2 revenue and 30% system growth signal a strong market position and investment opportunity.
- SS Innovations' Q2 revenue rose 39.4% to $13.9M, with gross margin 50.9%, net loss $2.7M, and 30 new installations.
- SS Innovations expands global access to robotic surgery via 224 systems in 12 countries and telesurgery across continents.
- SS Innovations completed a telesurgery spanning over 13,600 miles between Colombia and India, a first for robotic surgery.
Impact - Why it Matters
This news is significant because SS Innovations is rapidly expanding its footprint in the surgical robotics market, with record revenue and installations underscoring growing adoption of its SSi Mantra system. The completion of a transcontinental telesurgery demonstrates the potential to bring expert surgical care to remote areas, potentially transforming healthcare access globally. With regulatory approvals pending in the U.S. and Europe, the company is on the cusp of entering major markets, which could intensify competition and drive down costs in robotic surgery, ultimately benefiting patients and healthcare systems worldwide.
Summary
SS Innovations International (NASDAQ: SSII), a developer of affordable surgical robotic technologies, announced record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10 million in the same period last year. The growth was driven by a 30.4% rise in installations of its SSi Mantra surgical robotic system, reaching 30 units in the quarter. Gross profit climbed 20% to $7.1 million, with a gross margin of 50.9%, while the net loss widened to $2.7 million, or $0.01 per diluted share, compared to a net loss of $0.3 million a year earlier. For the first half of 2026, revenue surged 65.6% to $25 million, with installations up 47.4% to 56. As of June 30, the company held $13.6 million in cash and cash equivalents, no long-term debt, and a cumulative installed base of 224 SSi Mantra systems across 12 countries.
The company reported 12,272 cumulative procedures using the SSi Mantra as of June 30, including 175 telesurgeries. Notably, SS Innovations completed a robotic telesurgery spanning more than 13,600 miles between Colombia and India, showcasing the system's remote capabilities. Looking ahead, the company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra's 510(k) premarket notification by the end of the first quarter of 2027, and it believes it can obtain European Union CE marking certification by the end of 2026. These regulatory milestones are crucial for expanding into major markets. To view the full press release, visit https://ibn.fm/nTMso.
SS Innovations International is an American company headquartered in India, focusing on making robotic surgery accessible globally through its SSi Mantra system and SSi Mudra instruments. The company's vision is to democratize advanced surgical technology, particularly for cardiac procedures. With a growing installed base and successful telesurgeries, SS Innovations is positioning itself as a key player in the global surgical robotics market, with a focus on cost-effectiveness and user-friendliness. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, SS Innovations Hits Record Q2 Revenue of $13.9M, Up 39.4%
